Suchergebnisse - (Subject:"Siltuximab")

PubPharm (8)

1

A New Approach to the Management of COVID-19. Antagonists of IL-6 : Siltuximab

enthalten in: Advances in therapy | 2022

von Villaescusa, L. | Zaragozá, F. | Gayo-Abeleira, I. | +1

2

Advances in clinical outcomes : What we have learned during the COVID-19 pandemic

enthalten in: The Journal of allergy and clinical immunology | 2022

von Al-Musa, A. | LaBere, B. | Habiballah, S. | +2

3

Immune-related adverse events of biological immunotherapies used in COVID-19

enthalten in: Frontiers in pharmacology | 2022

von Baracaldo-Santamaría, D. | Barros-Arias, G. | Hernández-Guerrero, F. | +2

4

The role of IL-6 and IL-6 blockade in COVID-19

enthalten in: Expert review of clinical immunology | 2021

von Potere, N. | Batticciotto, A. | Vecchié, A. | +5

5

Pharmacological treatment of COVID-19 : Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)

enthalten in: Medicina intensiva | 2021

von Díaz, E. | Amézaga Menéndez, R. | Vidal Cortés, P. | +6

6

Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome

enthalten in: International journal of medical sciences | 2021

von Du, P. | Geng, J. | Wang, F. | +3

7

Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease

enthalten in: Expert opinion on investigational drugs | 2020

von Zhou, Z. | Price, C.

8

Cytokine storm intervention in the early stages of COVID-19 pneumonia

enthalten in: Cytokine & growth factor reviews | 2020

von Sun, X. | Wang, T. | Cai, D. | +9

CommentIn: Cytokine Growth Factor Rev. 2021 Apr;58:30-31. - PMID 32873506

1
[1]